Treatment of intermediate-stage hepatocellular carcinoma

Nature Reviews Clinical Oncology

Volumn 11, Issue 9, 2014, Pages 525-535

  Forner, Alejandro ^a   Gilabert, Marine ^b   Bruix, Jordi ^a   Raoul, Jean Luc ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; CISPLATIN; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; LINIFANIB; RAMUCIRUMAB; SIRSPHERES; SORAFENIB; SUNITINIB; THERASPHERE; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTINEOPLASTIC ACTIVITY; BARCELONA CLINIC LIVER CANCER; CANCER GROWTH; CANCER STAGING; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COHORT ANALYSIS; CONSERVATIVE TREATMENT; DEVICE SAFETY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG TOLERANCE; EMBOLIC PARTICLE; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; REVIEW; RISK FACTOR; STANDARDIZATION; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR NECROSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; YTTRIUM RADIOISOTOPES;

EID: 85047691820     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.122     Document Type: Review

References (129)

1. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012
2. El-Serag, H. B. & Mason, A. C. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340, 745-750 (1999
3. WHO International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Prevalence and Mortality Worldwide in 2012 [online], http://globocan.iarc.fr/Pages/fact-sheets-population.aspx (2014
4. Sangiovanni, A. et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 43, 1303-1310 (2006
5. Cabibbo, G. et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51, 1274-1283 (2010
6. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28, 751-755 (1998
7. Vauthey, J. N. et al. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 20, 1527-1536 (2002
8. Kudo, M. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology 40, 1396-1405 (2004
9. Tateishi, R. et al. Proposal of a new prognostic model for hepatocellular carcinoma: An analysis of 403 patients. Gut 54, 419-425 (2005
10. Hsu, C. Y. et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: The Taipei Integrated Scoring System. J. Hepatol. 53, 108-117 (2010
11. Forner, A., Reig, M. E., de Lope, C. R. & Bruix, J. Current strategy for staging and treatment: The BCLC update and future prospects. Semin. Liver Dis. 30, 61-74 (2010
12. Yau, T. et al. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146, 1691-1700 (2014
13. Collette, S. et al. Prognosis of advanced hepatocellular carcinoma: Comparison of three staging systems in two French clinical trials. Ann. Oncol. 19, 1117-1126 (2008
14. Huitzil-Melendez, F. D. et al. Advanced hepatocellular carcinoma: Which staging systems best predict prognosis? J. Clin. Oncol. 28, 2889-2895 (2010
15. Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646-649 (1973
16. Sorensen, J. B., Klee, M., Palshof, T. & Hansen, H. H. Performance status assessment in cancer patients. An inter-observer variability study. Br. J. Cancer 67, 773-775 (1993
17. Bruix, J. & Sherman, M. Management of hepatocellular carcinoma: An update. Hepatology 53, 1020-1022 (2011
18. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012
19. D'Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J. Hepatol. 44, 217-231 (2006
20. Tsochatzis, E. A., Bosch, J. & Burroughs, A. K. Liver cirrhosis. Lancet 383, 1749-1761 (2014
21. Cillo, U et al. The critical issue of hepatocellular carcinoma prognostic classification: Which is the best tool available? J. Hepatol. 40, 124-131 (2004
22. Marrero, J. A. et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort. Hepatology 41, 707-716 (2005
23. Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis. 19, 329-338 (1999
24. Llovet, J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359, 1734-1739 (2002
25. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008
26. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009
27. Ferenci, P. et al. Hepatocellular carcinoma (HCC): A global perspective. J. Clin. Gastroenterol. 44, 239-245 (2010
28. Verslype, C., Rosmorduc, O. & Rougier, P. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, vii41-vii48 (2012
29. Beaugrand, M. et al. Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): An International randomized double-blind placebo-controlled study in 747 patients. J. Hepatol. 42, 17A (2005
30. Bruix, J. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J. Hepatol. 57, 821-829 (2012
31. Llovet, J. M. et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 29, 62-67 (1999
32. Bolondi, L. et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions. Semin. Liver Dis. 32, 348-359 (2012
33. Livraghi, T. et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology 197, 101-108 (1995
34. Imamura, H. et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 38, 200-207 (2003
35. Ikai, I. et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101, 796-802 (2004
36. Todo, S. & Furukawa, H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: Experience in Japan. Ann. Surg. 240, 451-459 (2004
37. Takayasu, K. et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8, 510 patients. Gastroenterology 131, 461-469 (2006
38. Zhu, A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: A phase II study. J. Clin. Oncol. 27, 3027-3035 (2009
39. N'Kontchou, G. et al. Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 50, 1475-1483 (2009
40. Merani, S. et al. The impact of waiting list alpha fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J. Hepatol. 55, 814-819 (2011
41. Duvoux, C. et al. Liver transplantation for hepatocellular carcinoma: A model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 143, 985-986 (2012
42. Llovet, J. M. et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 18, 2290-2300 (2012
43. Chevret, S. et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J. Hepatol. 31, 133-141 (1999
44. Leung, T. W. et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 94, 1760-1769 (2002
45. Kitai, S. et al. Validation of a new prognostic staging system for hepatocellular carcinoma: A comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 75 (Suppl. 1), 83-90 (2008
46. Camma, C. et al. Survival of patients with hepatocellular carcinoma in cirrhosis: A comparison of BCLC, CLIP and GRETCH staging systems. Aliment. Pharmacol. Ther. 28, 62-75 (2008
47. Llovet, J. M. & Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37, 429-442 (2003
48. Lo, C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164-1171 (2002
49. Kudo, M. et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 29, 339-364 (2011
50. Benson, A. B. et al. NCCN clinical practice guidelines in oncology: Hepatobiliary cancers. J. Natl Compr. Canc. Netw. 7, 350-391 (2009
51. Omata, M. et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol. Int. 4, 439-474 (2010
52. Lencioni, R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 52, 762-773 (2010
53. Raoul, J. L. et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70, 585-590 (1992
54. Kwok, P. C. et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J. Hepatol. 32, 955-964 (2000
55. Bruix, J. et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution. Hepatology 27, 1578-1583 (1998
56. Varela, M. et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J. Hepatol. 46, 474-481 (2007
57. Furuse, J. et al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am. J. Clin. Oncol. 26, 159-164 (2003
58. Lee, K. H. et al. Evaluation of different calibrated spherical polyvinyl alcohol microspheres in transcatheter arterial chemoembolization: VX2 tumor model in rabbit liver. J. Vasc. Interv. Radiol. 19, 1065-1069 (2008
59. Chen, M. S. et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J. Gastroenterol. 8, 74-78 (2002
60. [No authors listed] A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N. Engl. J. Med. 332, 1256-1261 (1995
61. Pelletier, G. et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Groupe CHC. J. Hepatol. 29, 129-134 (1998
62. Oliveri, R. S., Wetterslev, J. & Gluud, C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Systematic Reviews, Issue 3. Art. No.: CD004787. http://dx.doi.org/10.1002/ 14651858.CD004787.pub2.
63. Ray, C. E. Jr, Haskal, Z. J., Geschwind, J. F. & Funaki, B. S. The use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: A response to the Cochrane Collaboration review of 2011. J. Vasc. Interv. Radiol. 22, 1693-1696 (2011
64. Forner, A., Llovet, J M. & Bruix, J. Chemoembolization for intermediate HCC: Is there proof of survival benefit? J. Hepatol. 56, 984-986 (2012
65. Raoul, J. et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat. Rev. 37, 212-220 (2011
66. Namur, J. et al. Drug-eluting beads for liver embolization: Concentration of doxorubicin in tissue and in beads in a pig model. J. Vasc. Interv. Radiol. 21, 259-267 (2010
67. Poon, R. T. et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin. Gastroenterol. Hepatol. 5, 1100-1108 (2007
68. Lammer, J. et al. Prospective randomized study of doxorubicin eluting bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc. Interv. Radiol. 33, 41-52 (2010
69. Burrel, M. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J. Hepatol. 56, 1330-1335 (2012
70. Malagari, K. et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: Five-year survival analysis. Cardiovasc. Interv. Radiol. 35, 1119-1128 (2012
71. Takayasu, K. et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: Propensity score analysis. AJR Am. J. Roentgenol. 194, 830-837 (2010
72. Takayasu, K. et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J. Hepatol. 56, 886-892 (2012
73. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92, 205-216 (2000
74. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009
75. Forner, A et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer 115, 616-623 (2008
76. Bruix, J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421-430 (2001
77. Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008
78. Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52-60 (2010
79. Riaz, A. et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 303, 1062-1069 (2010
80. Bargellini, I. et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT pathologic correlation in 178 liver explants. Eur. J. Radiol. 82, e212-e218 (2013
81. Golfieri, R. et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small
82. Riaz, A. et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: Radiologic-pathologic correlation. J. Hepatol. 54, 695-704 (2011
83. Gillmore, R. et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J. Hepatol. 55, 1309-1316 (2011
84. Memon, K. et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141, 526-535 (2011
85. Prajapati, H. J. et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann. Oncol. 24, 965-973 (2013
86. Choi, J. et al. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma. J. Hepatol. 60, 1212-1218 (2014
87. Lencioni, R. et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: A pilot clinical study. J. Hepatol. 49, 217-222 (2008
88. Peng, Z. W. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial. J. Clin. Oncol. 31, 426-432 (2013
89. Wang, W., Shi, J. & Xie, W. F. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: A meta-analysis. Liver Int. 30, 741-749 (2010
90. Ni, J., Liu, S., Xu, L., Sun, H. & Chen, Y. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: A meta-analysis. J. Cancer Res. Clin. Oncol. 139, 653-659 (2013
91. Lu, Z. et al. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: A meta-analysis of randomized-controlled trials. Eur. J. Gastroenterol. Hepatol. 25, 187-194 (2013
92. Lencioni, R. et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): Technical recommendations. Cardiovasc. Intervent. Radiol. 35, 980-985 (2012
93. Park, J. W. et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 33, 327-337 (2013
94. Sergio, A. et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): The role of angiogenesis and invasiveness. Am. J. Gastroenterol. 103, 914-921 (2008
95. Sieghart, W. et al. The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 57, 2261-2273 (2013
96. Hucke, F. et al. The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re treated with TACE. J. Hepatol. 60, 118-126 (2014
97. Bruix, J. et al. Clinical decision making and research in hepatocellular carcinoma: Pivotal role of imaging techniques. Hepatology 54, 2238-2244 (2011
98. Dufour, J. F. et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: Results of a phase I study. Oncologist 15, 1198-1204 (2010
99. Lencioni, R. et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial [abstract]. J. Clin. Oncol. 30, LBA154 (2012
100. Chung, Y. H. et al. Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int. J. Cancer 132, 2448-2458 (2013
101. Kudo, M et al. A randomized, doubled-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: Initial results [abstract O-022]. Presented at the 7th ILCA Annual Conference 2013.
102. Yeo, W. et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl Cancer Inst. 97, 1532-1538 (2005
103. Louafi, S. et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study. Cancer 109, 1384-1390 (2007
104. Gish, R. G. et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol. 25, 3069-3075 (2007
105. Boige, V. et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br. J. Cancer 97, 862-867 (2007
106. Edeline, J. et al. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. World J. Gastroenterol. 15, 713-716 (2009
107. Davila, J. A., Duan, Z., McGlynn, K. A. & El Serag, H. B. Utilization and outcomes of palliative therapy for hepatocellular carcinoma: A population-based study in the United States. J. Clin. Gastroenterol. 46, 71-77 (2012
108. Qin, S. et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31, 3501-3508 (2013
109. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000
110. Hanahan, D. & Weinberg, A. Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011
111. Villanueva, A. & Llovet, J. M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410-1426 (2011
112. Cheng, A. L. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial. J. Clin. Oncol. 31, 4067-4075 (2013
113. Llovet, J. M. et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 31, 3509-3516 (2013
114. Johnson, P. J. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517-3524 (2013
115. Zhu, A. X. et al. EVOLVE 1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib [abstract]. J. Clin. Oncol. 32, a172 (2014
116. Forner, A. et al. Diagnosis and treatment of hepatocellular carcinoma [Spanish]. Med. Clin. (Barc.) 132, 272-287 (2009
117. Reig, M. et al. Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. Hepatology 58, 2023-2031 (2013
118. Raoul, J. L., Boucher, E., Rolland, Y. & Garin, E. Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat. Rev. Gastroenterol. Hepatol. 7, 41-49 (2010
119. Sangro, B., Inarrairaegui, M. & Bilbao, J. I. Radioembolization for hepatocellular carcinoma. J. Hepatol. 56, 464-473 (2012
120. Riaz, A. et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium 90 microspheres. Hepatology 49, 1185-1193 (2009
121. Kulik, L. M. et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47, 71-81 (2008
122. Salem, R. et al. Radioembolization for hepatocellular carcinoma using Yttrium 90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 138, 52-64 (2010
123. Hilgard, P. et al. Radioembolization with yttrium 90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 52, 1741-1749 (2010
124. Sangro, B. et al. Survival after yttrium 90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology 54, 868-878 (2011
125. Mazzaferro, V. et al. Yttrium 90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology 57, 1826-1837 (2013
126. Salem, R. et al. Radioembolization results in longer time to progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140, 497-507 (2011
127. Sangro, B. et al. Liver disease induced by radioembolization of liver tumors: Description and possible risk factors. Cancer 112, 1538-1546 (2008
128. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01381211?term=NCT01381211&rank=1 (2013
129. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00956930?term=NCT00956930&rank=1 (2014)